Here they are:

Acomplia, the Sanofi-Aventis fat pill;

Cervarix, the Glaxo HPV vaccine;

Galvus, the Novartis diabetes pill;

Gardasil, the Merck HPV vaccine;

Januvia/Janumet, the Merck diabetes treatment;

Nexavar, the Bayer cancer drug;

Prasugrel, the Lilly anti-platelet agent;

Pristiq, another Wyeth antidepressant;

Sutent, a Pfizer cancer drug;

Tykerb, a Glaxo cancer med.

This is according to Standard & Poor’s drug-industry analyst Arthur Wong, who writes:

We believe “that the pharmaceutical industry will get a breather of fewer patent expirations in 2008 to 2010, which will lessen pressure on big pharma R&D pipelines to constantly replace high-margin sales lost to generics. In addition, prospects in the pipelines are rapidly improving. While still by no means considered full, big pharma’s near-term pipelines and R&F productivity have been improving, with a number of signficant new product launches or upcoming launches from Merck, Sanofi-Aventis, Wyeth and Pfizer.

For our fourth annual installment of this report, Standard & Poor’s selected 10 of the most promising new products and prospects from rated global pharmaceutical companies, based on our opinion of their potential to generate blockbuster sales and their relative importance to the credit ratings on their respective manufacturers.

The list includes only new chemical entities that are expected to be submitted for regulatory approval or are entering their first full year on the market in 2007. Sales of the selectedd products might not be very significant in the intermediate term, especially to the companies’ overall business. However, by the time the next major wave of drugs loses patent protection, in about 2010-2012, these new drugs and prospects are expected to be mainstay products of their companies’ portfolios.”

[tags]Acomplia, Cervarix, Gardasil, Janumet; Galvus, Januvia, Nexavar, Prasugrel, Pristiq, Standard & Poor’s, Sutent, Tykerb[/tags]